Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present CytRx Corp. (NASDAQ: CYTR).

Full DD Report for CYTR

You must become a subscriber to view this report.


Recent News from (NASDAQ: CYTR)

CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data to be Presented at the American Society of Clinical Oncology 2018 Annual Meeting
LOS ANGELES , May 17, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that clinical data showing the lack of cardiac toxicity associated with treatment with partner NantCell's aldo...
Source: PR Newswire
Date: May, 17 2018 09:00
CytRx Announces Closing of $7.0 Million Registered Direct Offering
LOS ANGELES , May 15, 2018 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the closing of its previously announced registered direct offering of 5,600,000 shares of its common stock, at a purc...
Source: PR Newswire
Date: May, 15 2018 16:44
Midday Gainers / Losers (05/11/2018)
Gainers:  ANFI +83% . HEAR +48% . TTD +40% . ARCB +28% . WOW +28% . OMER +24% . MOSY +24% . BOXL +20% . BLNK +20% . EOLS +17% . More news on: Amira Nature Foods, Turtle Beach Corporation, The Trade Desk, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 11 2018 12:41
CytRx announces $7M registered direct offering; shares down 28% premarket
CytRx Corporation (NASDAQ: CYTR ) has entered into definitive purchase agreements with certain institutional investors to sell in a registered direct offering 5.6M shares of its common stock, at a purchase price of $1.25 per share. More news on: CytRx Corporation, Healthcare stocks news,...
Source: SeekingAlpha
Date: May, 11 2018 09:21
Premarket Losers as of 9:05 am (5/11/2018)
SBOT   -41%  on pricing equity offering. More news on: Stellar Biotechnologies Inc., Symantec Corporation, CytRx Corporation, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: May, 11 2018 09:14
CytRx Announces $7.0 Million Registered Direct Offering
LOS ANGELES , May 11, 2018 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has entered into definitive purchase agreements with certain institutional investors to sell in a registered ...
Source: PR Newswire
Date: May, 11 2018 08:00
CytRx Reports First Quarter 2018 Financial Results
LOS ANGELES , May 8, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced financial results for the quarter ended March 31, 2018 , and provided an overview of recent accomplishments and plans...
Source: PR Newswire
Date: May, 08 2018 08:30
CytRx Corporation to Present at OneMed NYC Oncology Investor Conference 2018
LOS ANGELES , May 7, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. Eric Curtis , President and Chief Operating Officer, will present at the OneMed NYC Oncology Investor Confer...
Source: PR Newswire
Date: May, 07 2018 09:00
CytRx Corporation Names Eric L. Curtis as Its President and Chief Operating Officer
LOS ANGELES , May 3, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its Board of Directors has approved the appointment of Eric L. Curtis , MBA, to the Company's executive man...
Source: PR Newswire
Date: May, 03 2018 08:30
CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Abstract Selected for Poster Presentation at the American Society of Clinical Oncology 2018 Annual Meeting
LOS ANGELES , April 30, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that an abstract submitted by aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC,...
Source: PR Newswire
Date: April, 30 2018 09:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-151.101.071.131.06111,033
2018-08-141.101.121.151.1080,746
2018-08-131.101.131.141.1081,891
2018-08-101.141.111.161.1164,683
2018-08-091.151.141.161.114154,347

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1517,49655,34531.6126Cover
2018-08-1421,21742,07850.4230Short
2018-08-1320,82943,24848.1618Short
2018-08-1025,90932,80778.9740Short
2018-08-0910,46520,14951.9381Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CYTR.


About CytRx Corp. (NASDAQ: CYTR)

Logo for CytRx Corp. (NASDAQ: CYTR)

Not available

 

Contact Information

 

 

Current Management

  • Steven Kriegsman / CEO
  • John Caloz / CFO
  • David Haen / VP, Business Development
  • Carrie Nodgaard / Director, Inv. Rel. amp Corp. Dev.

Current Share Structure

  • Market Cap: $47,813,107 - 03/20/2018
  • Issue and Outstanding: 27,637,634 - 11/07/2017

 


Recent Filings from (NASDAQ: CYTR)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 16 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: May, 15 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: May, 11 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: May, 11 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 07 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 07 2018

 

 


Daily Technical Chart for (NASDAQ: CYTR)

Daily Technical Chart for (NASDAQ: CYTR)


Stay tuned for daily updates and more on (NASDAQ: CYTR)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CYTR)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CYTR is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CYTR and does not buy, sell, or trade any shares of CYTR. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/